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for Accurate Identification of Disease-Causing Alleles
in Single Individuals and Small Nuclear Families
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Rebecca L. Margraf,4 Jacob Durtschi,4 Karen Eilbeck,2,7 Martin G. Reese,8 Lynn B. Jorde,1,2
Chad D. Huff,9 and Mark Yandell1,2,*
Phevor integrates phenotype, gene function, and disease information with personal genomic data for improved power to identify
disease-causing alleles. Phevor works by combining knowledge resident in multiple biomedical ontologies with the outputs of
variant-prioritization tools. It does so by using an algorithm that propagates information across and between ontologies. This process
enables Phevor to accurately reprioritize potentially damaging alleles identified by variant-prioritization tools in light of gene function,
disease, and phenotype knowledge. Phevor is especially useful for single-exome and family-trio-based diagnostic analyses, the most
commonly occurring clinical scenarios and ones for which existing personal genome diagnostic tools are most inaccurate and under-
powered. Here, we present a series of benchmark analyses illustrating Phevor’s performance characteristics. Also presented are three
recent Utah Genome Project case studies in which Phevor was used to identify disease-causing alleles. Collectively, these results show
that Phevor improves diagnostic accuracy not only for individuals presenting with established disease phenotypes but also for those
with previously undescribed and atypical disease presentations. Importantly, Phevor is not limited to known diseases or known
disease-causing alleles. As we demonstrate, Phevor can also use latent information in ontologies to discover genes and disease-causing
alleles not previously associated with disease.Introduction
Personal genome sequencing is dramatically changing
the landscape of clinical genetics, but it also presents a
host of challenges. Every sequenced exome presents the
clinical geneticist with thousands of variants, any one of
which might be responsible for the person’s illness. One
approach to making sense of these data is to employ a
whole-genome and whole-exome search tool such as
ANNOVAR1 or the Variant Annotation, Analysis, Search
Tool (VAAST)2,3 to identify disease-causing variants in an
ab initio fashion. This is proving an effective approach
for case-cohort analyses;4–8 likewise, sequencing addi-
tional family members can also improve diagnostic accu-
racy. Unfortunately, single affected individuals and small
nuclear families are the most frequently encountered
diagnostic scenarios in the clinic. Today’s whole-genome
and whole-exome search and variant-prioritization tools
are underpowered in these situations, limiting the
number of successful diagnoses.2,9 In response, physicians
and clinical genetics laboratories often attempt to narrow
the list to a subset of candidate genes and alleles in light
of an individual’s phenotype.10
Phenotype data are generally employed in an ad hoc
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The Amand alleles as candidates on the basis of their expert
knowledge. No general standards, procedures, or validated
best practices yet exist. Moreover, genes not previously
associated with the phenotype are not considered—often
preventing the discovery of gene-disease associations.
The potential impact of false positives and negatives on
diagnostic accuracy is obviously considerable. Algorithmic
means of prioritizing genes and variants in light of pheno-
type data are thus badly needed. In response, we have
created Phevor, the Phenotype Driven Variant Ontological
Re-ranking tool.
Phevor works by combining the outputs of widely used
variant-prioritization tools with knowledge resident in
diverse biomedical ontologies, such as the Human Pheno-
type Ontology (HPO),11 the Mammalian Phenotype
Ontology (MPO),12 the Disease Ontology (DO),13 and the
Gene Ontology (GO)14 (Figure S1, available online). Ontol-
ogies are graphical representations of the knowledge, such
as gene functions or human phenotypes, in a given
domain. Ontologies organize this knowledge by using
directed acyclic graphs wherein concepts (terms) are nodes
in the graph and the logical relationships obtained
between them are modeled as edges, for example, ‘‘deami-
nase activity’’ (node) is_a (edge) ‘‘catalytic activity’’
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biological data, rendering the data machine readable and
traversable via the ontologies’ relationships (edges). For
example, annotating a gene with the term ‘‘deaminase
activity’’ makes it possible to deduce that the same gene
encodes a protein with ‘‘catalytic activity.’’ In recent years,
many biomedical ontologies have been created for the
management of biological data.15–17
Phevor propagates an individual’s phenotype informa-
tion across and between biomedical ontologies. This pro-
cess enables Phevor to accurately reprioritize candidates
identified by variant-prioritization tools in light of knowl-
edge contained in the ontologies. As we show, Phevor
can also discover emergent gene properties and latent
phenotype information by combining ontologies, further
improving its accuracy.
Phevor does not replace existing prioritization tools;
rather, it provides a general means of improving every
tool’s performance. As we demonstrate, Phevor substan-
tially improves the accuracy of widely used variant-priori-
tization tools such as SIFT,18 conservation-based tools
such as PhastCons,19 and genome-wide search tools such
as VAAST2,3 and ANNOVAR.1 Phevor also outperforms
tools such as PHIVE (Phenotypic Interpretation of Variants
in Exomes),20 which combines a fixed-variant filtering
approach with mouse phenotype data.
Phevor also differs from tools such as Phenomizer21 and
sSAGA (Symptom- and Sign-Assisted Genome Analysis)10
in that it does not postulate a set of fixed associations
between genes, phenotypes, and diseases. Rather, Phevor
dynamically integrates knowledge resident in multiple
biomedical ontologies into the variant-prioritization pro-
cess. This enables Phevor to improve diagnostic accuracy
not only for established disease phenotypes but also for
previously undescribed and atypical disease presentations.
Importantly, Phevor also provides ameans of integrating
ontologies that contain knowledge not explicitly linked to
phenotype (such as the GO) into the variant-prioritization
process. As we demonstrate, Phevor can use information
latent in such ontologies to discover disease-causing alleles
in genes not previously associated with disease.
Phevor is especially useful for single-exome and family-
trio-based diagnostic analyses, the most commonly
occurring clinical scenarios and ones for which existing
sequenced-based diagnostic tools are most inaccurate and
underpowered. Here, we describe the algorithm under-
lying Phevor and present benchmark analyses illustrating
Phevor’s performance characteristics.We also present three
Utah Genome Project clinical applications in which Phe-
vor was used to identify both known disease-causing alleles
and ones not previously associated with disease.Material and Methods
Phenotype and Candidate-Gene Information
Phevor can improve diagnostic accuracy by using phenotype and
candidate-gene information derived from multiple sources. In the600 The American Journal of Human Genetics 94, 599–610, April 3, 2simplest scenario, users provide a tab-delimited list of terms
describing the phenotype(s) drawn from the HPO.11 Alternatively,
the list can consist of terms from the DO,13 MPO,12 GO,14 or
Online Mendelian Inheritance in Man (OMIM). Lists containing
terms from more than one ontology are also permitted. Users
may also employ the online tool Phenomizer21 to describe an
individual’s phenotype and to assemble a list of candidate genes.
Phenomizer provides the physician with a means of producing a
phenotype description for use with Phevor. The Phenomizer
report can be downloaded to the user’s computer and passed
directly to Phevor. See Figure S1 for more information.Assembling a Gene List
Biomedical-ontology annotations are now readily available for
many human and model-organism genes. Probably the best-
known example is the GO. Currently, over 18,000 human genes
have been annotated with GO terms.14 In addition, at last count,
over 2,800 human genes have been annotated with HPO terms.11
Phevor employs these annotations to associate ontology concepts
(nodes) to genes and vice versa. Consider the following example of
a phenotype description consisting of two HPO terms: ‘‘hypo-
thyroidism’’ (HP:0000812) and ‘‘abnormality of the intestine’’
(HP:0002242). If genes have previously been annotated to these
two nodes in the ontology, Phevor saves those genes in an internal
list. In cases where no genes are annotated to a user-provided
ontology term, Phevor traverses that ontology by beginning at
the provided term and proceeding toward the ontology’s root(s)
until it encounters a node with annotated genes, and then it
adds those genes to the list. At the end of this process, the resulting
gene list is then used for seeding nodes in the other ontologies,
e.g., the GO, MPO, and DO.
Phevor relates different ontologies via their common gene
annotations (Figure S2). Deleterious alleles in ABCB11, for
example, are known to cause intrahepatic cholestasis, a fact
captured by HPO’s annotation of ABCB11 to the node ‘‘intrahe-
patic cholestasis’’ (HP:0001406). In the GO, ABCB11 is annotated
to ‘‘canalicular bile acid transport’’ (GO:0015722) and ‘‘bile acid
biosynthetic process’’ (GO:0006699). Phevor uses the common
gene (in this case, ABCB11) to relate the HPO node HP:0001406
to GO nodes GO:0015722 and GO:0006699. As we explain below,
this process allows Phevor to extend its search to include addi-
tional genes with functions similar to those of ABCB11.Ontology Propagation
Once Phevor identifies a set of starting nodes for each ontology,
i.e., those provided by the user in their phenotype list (e.g.,
HP:0001406) or those derived from it by the cross-ontology
linking procedure described in the preceding paragraph (e.g.,
GO:0015722 and GO:0006699), it next propagates this informa-
tion across each ontology by means of a process we term ontolog-
ical propagation. Consider the example shown in Figure S3. Here,
two seed nodes in some ontology have been identified, and in
both cases gene A has been previously annotated to both nodes.
Each seed node is assigned a value of 1, and this information is
then propagated across the ontology as follows. If we proceed
from each seed node toward its children, each time an edge is
crossed to a neighboring node, the current value of the previous
node is divided by 2. For example, if the starting seed node has
two children, its value is divided in half for each child, so in this
case, both children receive a value of 1/2 . This process is continued
until a terminal leaf is encountered. The original seed scores are014
also propagated upward to the root node(s) of the ontology by
means of the same procedure (Figure S3B). In practice, there can
be many seed nodes. In such cases, intersecting threads of propa-
gation are first added together, and the process of propagation
then proceeds as previously described. One interesting conse-
quence of this process is that nodes far from the original seeds
can attain high values, greater even than those of any of the start-
ing seed nodes. The phenomenon is illustrated by the darker red
nodes in Figure S3C, in which propagation has identified two addi-
tional gene candidates, B and C, not associated with the original
seed nodes.
From Node to Gene
Upon completion of propagation (Figure S3C), Phevor renormal-
izes each node’s value to between 0 and 1 by dividing it by the
sum of all node scores in the ontology. Phevor next assigns each
gene annotated to the ontology a score corresponding to the
maximum score of any node in the ontology to which it is
annotated. This process is repeated for each ontology; thus, genes
annotated to more than one ontology will have a score from each.
These scores are added to produce a final sum score for each gene
and renormalized again to a value between 0 and 1. Consider a set
of genes drawn from the HPO and assigned gene scores by the pro-
cess described in the preceding paragraphs. Consider also a similar
list of human genes derived from propagation across the GO. Sim-
ply summing each gene’s HPO and GO scores and renormalizing
again by the total sum of sums will combine these lists.
Rational Expansion of Candidate-Gene Lists
The ontological propagation and combination procedures
described above enable Phevor to extend the original HPO-derived
gene list into an expanded candidate-gene list that can also
include genes not annotated to the HPO. Recall that during
propagation across an ontology, intersecting threads can cause
nodes to have scores that equal or even exceed those of any orig-
inal seed nodes. Thus, a gene not yet associated with a particular
human disease can become an excellent candidate if it is anno-
tated to an HPO node located at an intersection of phenotypes
associated with other diseases or has GO functions, locations,
and/or processes similar to those of known disease-genes anno-
tated to HPO. Phevor also employs the MPO, allowing it to
leverage model-organism phenotype information, and the DO,
which provides it with additional information pertaining
to human genetic disease. Thus, Phevor’s approach provides
an automatic and rational means of expanding a candidate-
gene list derived from a starting list of phenotype or gene-
function terms to leverage knowledge contained in diverse
biomedical ontologies. In the paragraphs below, we explain how
gene sum scores are combined with the outputs of variant-priori-
tization tools for improving the accuracy of sequence-based
diagnosis.
Combining Ontologies and Variant Data
Upon completion of all ontology propagation, combination, and
gene-scoring steps described in the preceding paragraphs, genes
are ranked by their gene sum scores; then, their percentile ranks
are combined with variant and gene-prioritization scores as
follows. Phevor first calculates a disease association score for
each gene,
Dg ¼

1 Vg

3Ng ; (Equation 1)The AmwhereNg is the percentile rank of the renormalized gene sum score
as derived from the ontological combination and propagation
procedures described in Figures S2 and S3 and Vg is the gene’s
percentile rank provided by the external variant-prioritization or
search tool, e.g., ANNOVAR, SIFT, or PhastCons (except for VAAST,
in which case its reported p values are used directly). Phevor then
calculates Hg , a second score summarizing the weight of evidence
that the gene is not involved with the individual’s illness, i.e.,
neither the variants nor the gene is involved in the individual’s
disease:
Hg ¼ Vg 3

1Ng

: (Equation 2)
The Phevor score (Equation 3) is the log10 ratio of the disease asso-
ciation score ðDgÞ and the healthy association score ðHgÞ,
Sg ¼ log10Dg

Hg : (Equation 3)
These scores are distributed normally (data not shown). The per-
formance benchmarks presented in the Results provide an objec-
tive basis for evaluating the utility of Sg .
Sequencing Procedures
To sequence exome DNA, we used the Agilent SureSelect(XT)
Human All Exon V5þUTRs targeted enrichment system. The
whole genome of the STAT1 proband was sequenced (see Results
for details). An Illumina HiSeq instrument programmed to
perform 101-cycle paired-end sequencing was used for all cases.
Sanger Sequence Validation
Putative disease-causing mutations identified by exome seq-
uencing were validated by Sanger sequencing in the DNA Seq-
uencing Core Facility at the University of Utah. We also used
DNA from probands and parents to validate inheritance patterns
or confirm de novo mutations in all of the cases presented. PCR
primers were designed and optimized and subsequently amplified.
Sequencing was performed via capillary sequencing.
Variant-Calling Procedures
According to the best practices described by the Broad Institute,23
sequence reads were aligned with the Burrows-Wheeler Aligner,
PCR duplicates were removed, and indel realignment was per-
formed with the Genome Analysis Toolkit (GATK). Variants were
joint called with the GATK UnifiedGenotyper in conjunction
with 30 CEU (Utah residents with ancestry from northern and
western Europe from the CEPH collection) Genome BAM files
from the 1000 Genomes Project.24 For the benchmarking experi-
ments, only single-nucleotide variants (SNVs) were used because
not every variant-prioritization tool can score indels and splice-
site variants. The case-study analyses searched SNVs, splice-site
variants, and indels.
Benchmarking Procedures
We inserted known, disease-causing alleles into otherwise healthy
(background) exomes. These exomes were sequenced to 503
coverage on an Illumina HiSeq (see sequencing procedures above)
and jointly called with 30 CEU genomes drawn from the 1000
Genomes Project.24 Known disease-associated genes were
randomly selected (without replacement) from the Human Gene
Mutation Database (HGMD). For each gene in the HGMD,
damaging SNV alleles were randomly selected (without replace-
ment) from all recorded damaging alleles at that locus. Theerican Journal of Human Genetics 94, 599–610, April 3, 2014 601
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the quality metrics of the closest mapped variant were attached to
it. Damaging alleles were inserted into the appropriate number of
healthy exomes depending on the inheritance model (e.g., two
copies of the same allele for recessive and one for dominant).
This process was repeated 100 times for 100 different, randomly
selected genes with established disease associations; the entire
process was then repeated 99 more times for determining margins
of error. All prioritization tools (SIFT, PhastCons, ANNOVAR, and
VAAST) were run with their default settings, except that dominant
or recessive inheritance was specified for the VAAST and
ANNOVAR runs because these two tools allow users to do so. For
purposes of comparison, for the VAAST and ANNOVAR runs, the
maximum minor allele frequency (MAF) cutoff was set to 1%,
ANNOVAR’s default setting. We also explored running ANNOVAR
with differentMAF cutoffs but found that overall performance was
best with this value. ANNOVAR was run with the ‘‘clinical variant
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Figure 1. Variant Prioritization for Known Disease-Causing
Alleles
Performance comparisons of four different variant-prioritization
tools before (A) and after (B) postprocessing them with Phevor.
Two copies of a known disease-causing allele were randomly
selected from HGMD and spiked into a single target exome at
the reported genomic location; hence, these results model simple,
recessive diseases. This process was repeated 100 times for 100
different, randomly selected already disease-associated genes for
determining margins of error. Bar charts show the percentage of
time for which the disease-associated gene was ranked among
the top ten candidates genome-wide (red) or among the top 100
candidates (blue); white denotes a rank greater than 100 in the
candidate list. For the Phevor analyses in (B), each tool’s output
files were fed to Phevor along with phenotype report containing
the HPO terms annotated to each disease-associated gene. The
table below the bar charts summarizes this information in more
detail. Bars do not reach 100% because of false negatives, i.e.,
not every tool is able to prioritize every disease-causing allele.
When the target gene’s disease-causing alleles were unscored or
predicted to be benign by a tool, the gene was placed at the
midpoint of the list of the 22,107 annotated human genes.Results
Benchmark Analyses
Figure 1A summarizes the ability of four different variant
tools—SIFT, ANNOVAR, PhastCons, and VAAST— to use
a single affected individual’s exome to identify recessive
disease-causing alleles within a known disease-associated
gene. These four tools were selected so as to include two
prominent conservation-based variant-prioritization tools
(SIFT and PhastCons) and two prominent genome-wide
search tools (ANNOVAR and VAAST). SIFT18 is a tool for
amino acid conservation and functional prediction, Phast-
Cons19 is a tool for sequence-conservation identification,
ANNOVAR1 filters on variant frequencies to search
genomes for disease-casing alleles, and VAAST2,3 is a prob-
abilistic disease-associated-gene finder that uses informa-
tion on variant frequency and amino acid conservation.
To assemble these data, we inserted two copies of a known
disease-causing allele randomly selected from HGMD25
(see Material and Methods for details) into a single target
exome and repeated the process 100 times for 100 different
genes with known disease associations in order to deter-
mine margins of error. For these analyses, we used only
SNVs, excluding indels and other types of variants because
not every variant-prioritization tool can score them.
The heights of the bars in Figure 1A summarize the per-
centage of the 100 trials in which the prioritization tool
scored the known disease-causing allele. Importantly, the
percentages in Figure 1A include all scored alleles whether
or not they were scored as deleterious. For example, SIFT602 The American Journal of Human Genetics 94, 599–610, April 3, 2scored 46% of the known disease-causing variants as either
deleterious or tolerated. It was unable to score the remain-
ing 54% of the alleles. ANNOVAR scored 95% of the alleles,
and VAAST and PhastCons scored every allele. These per-
centages vary because not every tool is capable of scoring014
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Figure 2. Variant Prioritization for Genes Previously Unassoci-
ated with Disease
The procedure used in Figure 1B was repeated, but instead the
disease-associated gene’s ontological annotations were removed
from all but the specified ontologies prior to running Phevor. For
economic reasons, only VAAST results are shown. Removing all
the disease-associated gene’s annotations from all ontologies
mimics the case of a previously unreported allele in a gene with
unknown GO function, process, and cellular location and no
previous association with a known disease or phenotype. This is
equivalent to running VAAST alone (‘‘none’’), and the leftmost
bar chart and table column summarize these results. The right-
hand bar and table column (‘‘All’’) summarize the results of
running VAAST and Phevor with the current ontological annota-
tions of the disease-associated gene. The ‘‘GO only’’ column
reports the results of removing the disease-associated gene’s
phenotype annotations, depicting discovery success with only
GO ontological annotations. This column models the ability of
Phevor to identify a disease association when that gene is anno-
tated to GO but has no disease, human, or model-organism
phenotype annotations. In contrast The ‘‘MPO, HPO, and DO’’
column assays the impact of removing a gene’s GO annotations
but leaving its disease, human, and model-organism phenotype
annotations intact.every potential disease-causing variant. The reasons vary
from tool to tool and case to case. SIFT, for example, cannot
score alleles located in poorly conserved coding regions of
genes.26
The colors of the bars in Figure 1A summarize the per-
centage of time the gene with the inserted disease-causing
alleles was ranked among the top ten candidates genome-
wide (red) or among the top 100 candidates (blue); white
denotes a rank greater than 100 in the candidate list. The
table in Figure 1A summarizes this information in more
detail. ANNOVAR, for example, ranked 95% of the genes
spiked with known disease-causing alleles as potentially
damaged and judged the remainder of these genes as
containing only nondeleterious alleles. Of the 95% of
damaged genes it detected, on average it ranked all of
them within the top 100 candidates genome-wide. For
the 5% of genes that ANNOVAR failed to rank, we assigned
a rank of 11,141—the midpoint of the annotated 22,107
human genes. Hence, the average rank was much lower:
3,653. VAAST, by comparison, ranked every gene and iden-The Amtified the disease-causing allele among the top 100 candi-
dates 99% of the time and gave an average rank of 83
genome-wide. Note that in 100 runs of 100 different test
cases, no tool ever placed the gene containing the
disease-causing alleles among the top ten candidates.
Figure 1A thus illustrates a basic fact of personal genome
analysis: using only a single affected exome, today’s
tools are underpowered to identify the damaged gene
and its disease-causing variants.
Figure 1B summarizes the results of using Phevor to
reanalyze the same SIFT, ANNOVAR, PhastCons, and
VAAST output files in Figure 1A. For these analyses, each
tool’s output files were provided to Phevor along with a
phenotype report containing the HPO terms annotated
to every gene with inserted disease-causing alleles. These
phenotype descriptions are provided in Table S1. As can
be seen, Phevor dramatically improved the performance
of every tool benchmarked in Figure 1A. For the 95% of
genes ranked by ANNOVAR, all were among the top ten
candidates, and Phevor improved the average rank for
ANNOVAR from 3,653 to 552. Similar trends were seen
for SIFT. Phevor showed even better improvements for
PhastCons and VAAST outputs. The average rank for
VAAST, for example, improved from 83 to 1.8, and the
gene containing the disease-causing alleles was ranked
among the top ten genes100% of the time. Phevor per-
formed best on VAAST outputs because VAAST has a lower
false-negative rate than SIFT and ANNOVAR (Figure 1A).
This is because Phevor only improves the ranks of priori-
tized genes; it doesn’t rerank genes previously determined
by a tool to harbor no deleterious alleles.
Results for dominant disease are provided in Figure S4.
As would be expected, benchmarks for dominant diseases
showed the same trends in that every tool exhibited lower
power than for recessive cases. However, Phevor still
markedly improved power. Using VAAST outputs, Phevor
ranked the gene containing the disease-causing variant
in the top ten candidates 93% of the time.
Collectively, these results demonstrate that Phevor can
improve the power of widely used variant-prioritization
tools. Recall, however, that the HPO provides a list of
~2,800 known human genes, each annotated to one or
more HPO nodes, and that Phevor uses this information
during the ontology combination and propagation steps
described in Figures S2 and S3 (see Material and Methods).
In light of this fact, the question naturally arises as to how
much Phevor depends on the fact that the gene with the
disease-causing allele(s) has been previously annotated to
an ontology. Figure 2 addresses this issue.
Figure 2 employs the same procedure as in Figure 1, but
instead the disease-associated gene was removed from one
or more of the ontologies prior to running Phevor.
This made it possible to evaluate Phevor’s ability to
improve the ranks of a gene containing disease-causing
alleles in the absence of any ontological assignments
(i.e., as if the gene had never before been associated with
a disease, function, or phenotype). For these benchmarks,erican Journal of Human Genetics 94, 599–610, April 3, 2014 603
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Figure 3. Comparison of Phevor to the Exomiser’s PHIVE
Comparison of disease-allele-identification success rates for Phe-
vor and the PHIVE methodology, which is available through the
Exomiser. The Exomiser is based upon ANNOVAR’s filtering logic;
thus, the Phevor comparison uses ANNOVAR as the variant-prior-
itization tool. Shown are the results of 100 searches of known
recessive disease-associated genes. Identical variant files and
phenotype descriptions were given to Exomiser þ PHIVE and
ANNOVAR þ Phevor. Bar charts show the percentage of time for
which the target, i.e., disease-associated, gene was ranked among
the top ten candidates genome-wide (red) or among the top 100
candidates (blue); white denotes a rank greater than 100 in the
candidate list. The table below the bar charts summarizes this
information in more detail. Bars do not reach 100% because of
false negatives, i.e., the tool reported the disease-causing allele to
be nondeleterious; these cases were placed at the midpoint of
the list of 22,107 annotated human genes.we investigated not only the impact of simultaneously
masking the gene’s HPO, MPO, and DO phenotype anno-
tations but also its GO annotations. Because of space
limitations, the results of these experiments are only
shown for VAAST outputs (Figure 2).
As can be seen, removing the gene from one or more
ontologies did decrease Phevor’s power to identify the
gene but did not eliminate it, demonstrating that Phevor
gained power by combining multiple ontologies.
Removing the target gene from the GO and using only
the three phenotype ontologies (HPO, MPO, and DO),
Phevor still ranked the target gene in the top ten candi-
dates 36% of the time and in the top 100 candidates 82%
of the time. By comparison, using VAAST alone, Phevor
ranked the target gene among the top 10 and 100 candi-
dates 0% and 99% of the time, respectively. The 18%
false-negative rate was an artifact of the benchmark proce-
dure and resulted from removing the gene from the GO. In
brief, because the majority of human genes (18,824) are
already annotated to the GO, the prior expectation is604 The American Journal of Human Genetics 94, 599–610, April 3, 2that any new gene playing a role in the disease is more
likely to be annotated to the GO than not, causing Phevor
to prefer candidates already annotated to the GO in this
benchmarking scenario.
Similar trends were seen with using the GO14 alone. This
time, removing the gene from the MPO, HPO, and DO,
Phevor placed the gene containing the disease-causing
alleles among the top ten candidates 21% of the time
and among the top 100 candidates 80% of the time—still
much better than when it used VAAST alone. Recall that
for this analysis, Phevor was only provided with a pheno-
type description—not GO terms—and that the gene
containing the inserted disease-causing alleles was
removed from every ontology containing any phenotype
data, e.g., the, HPO, DO, andMPO. Thus, this rank increase
(e.g., from 0% to 21% in the top ten) was solely the result
of Phevor’s ability to integrate the GO into a phenotype-
driven prioritization process, demonstrating that Phevor
can use the GO to aid in the discovery of disease-causing
alleles in genes not previously associated with a given
disease phenotype. Collectively, these results demonstrate
that a significant portion of Phevor’s power is derived
from its ability to relate phenotype concepts in the HPO
to gene function, process, and location concepts modeled
by the GO.
Figure 2 demonstrates that Phevor improved the perfor-
mance of the variant-prioritization tool even when the
disease-causing alleles were located within genes with no
prior disease association. This is possible because even
when the gene containing the (novel) disease allele(s) is
absent from the HPO, Phevor can nonetheless assign it a
high score for disease association ðNgÞ after information
associated with its paralogs is propagated by Phevor from
the HPO to GO. This is a complex point, and an illustration
is helpful. Consider the case for two potassium-trans-
porter-encoding genes, A and B. Deleterious alleles in one
(A) are known to cause cardiomyopathy, whereas gene B
has no disease associations as of yet. If genes A and B are
both annotated in the GO as ‘‘potassium transporters,’’
when Phevor propagates the HPO associations of gene A
to the GO, the GO node ‘‘potassium transporter’’ will
receive some score, which in turn will be propagated to
gene B. Thus, even though gene B is absent from the
HPO, its Phevor disease association score will increase
because of its GO annotation. This illustrates the simplest
of cases. Many more-complex scenarios are possible. For
example, genes A and B might be annotated to different
nodes in the GO, in which case gene B’s disease association
score would increase proportionally after propagation
across the GO.
Figure 3 compares the relative performance of Phevor
to PHIVE,20 an online tool that uses ANNOVAR in
conjunction with mouse phenotype data to improve
ANNOVAR’s prioritization accuracy. PHIVE is accessible
through the Exomiser.20 For this benchmark, repeating
the process in Figure 1, we once again inserted two copies
of a known disease-causing allele randomly selected from014
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Figure 4. Phevor Accuracy and Atypical Disease Presentation
In order to evaluate the impact of incorrect diagnosis or atypical
phenotypic presentation on Phevor’s accuracy, we repeated the
analysis shown in Figure 1; this time, we randomly shuffled
the phenotype descriptions for each gene at runtime and used
the same phenotype descriptions for every member of a case
cohort. For economic reasons, only VAAST results are shown.
The results of running VAAST with and without Phevor for case
cohorts of one, three, and five unrelated individuals are shown.
As would be expected, providing Phevor with incorrect phenotype
data significantly affected its diagnostic accuracy. For a single
affected individual, Phevor declined in accuracy from ranking
the damaged gene in the top ten candidates genome-wide in
100% of the cases to ranking it in 26% of cases. Nevertheless, Phe-
vor was still able to improve upon VAAST’s performance alone.
Phevor placed 95% of the damaged genes in the top ten candidates
with cohorts of three and five unrelated affected individuals,
despite the misleading phenotype data, given that the additional
statistical power provided by VAAST increasingly outweighed the
incorrect prior probabilities provided by Phevor.HGMD25 (see Material and Methods for details) into a
target exome and repeated the process for 100 different
genes. The left column in Figure 3 provides a breakdown
of the results when ANNOVAR was used alone, the middle
column reports the results of uploading these same 100
exomes with their unprioritized variants to the Exomiser,
and the right column shows the results for the same 100
exomes with the use of ANNOVAR and Phevor. Although
the Exomiser did increase the percentage of cases for which
the target gene was located in the top 10 and top 100
candidates in comparison to ANNOVAR alone, it did so
at the expense of additional false negatives. In contrast,
Phevor obtained much better power on the same data set
(right column in Figure 3) without incurring any addi-
tional false negatives. Phevor was, however, ultimately
limited by ANNOVAR’s false-negative rate. This limitation
can be overcome simply by means of using VAAST reports
instead of ANNOVAR reports, in which case Phevor placesThe Am100%of the target genes among the top ten candidates (c.f.
Figure 1B).
Next, we sought to determine the impact of atypical dis-
ease presentation upon Phevor’s accuracy. The term atyp-
ical presentation refers to cases in which an individual has
a known genetic disease but does not present with the
typical disease phenotype. Reasons include previously
unreported alleles in known genes, previously undescribed
combinations of alleles, ethnicity (genetic-background
effects), environmental influences, and in some cases,
multiple genetic diseases presenting in the same individual
to produce a compound phenotype.27 Atypical presenta-
tion resulting from previously unreported disease-associ-
ated alleles in known genes and compound phenotypes
due to multiple disease-causing alleles are emerging as
a common occurrence in personal genome-driven diag-
nosis;9,27,28 thus, Phevor’s performance in such situations
is of interest.
Although a truly thorough investigation of atypical
presentation lies outside the scope of the current study,
Figure 4 addresses its impact on Phevor for case cohorts
of one, three, and five unrelated individuals by showing
the same benchmarking methodology as in Figure 1. For
this experiment, however, we randomly replaced each
target gene’s HPO-based phenotype description with an-
other’s, thereby mimicking an extreme scenario of atypical
presentation and/or misdiagnosis whereby each individual
presents with not only an atypical phenotype but also one
normally associated with some other known genetic dis-
ease. Unsurprisingly, this significantly affected Phevor’s
diagnostic accuracy. Using VAAST outputs for a single
affected individual, Phevor declined in accuracy from
ranking the damaged gene in the top ten candidates
genome-wide in 100% of the cases to ranking it in only
26% of the cases. More surprising is that Phevor was still
able to improve on VAAST’s performance alone, a phenom-
enon resulting again from Phevor’s use of the GO (as in
Figure 3) and a point that we address in more detail in
our Discussion.
The remaining columns in Figure 4 measure the impact
of increasing the size of the case cohort. As can be seen,
with three or more unrelated individuals all with the
same (shuffled) atypical phenotypic presentation, Phevor
performed very well, even when the phenotype informa-
tion was misleading. Thus, these results demonstrate
how Phevor’s ontology-derived scores, e.g., Ng in Equa-
tions 1 and 2, are gradually overridden in the face of
increasing sequence-based experimental evidence to the
contrary—a clearly desirable behavior.
Application of Phevor in the Clinic
We present three recent Utah Genome Project cases in
which we employed Phevor in tandem with ANNOVAR
and VAAST to identify disease-causing alleles in individuals
with an undiagnosed disease of a most likely genetic cause.
All three applications of Phevor involved either small
families or single affected individuals—scenarios forerican Journal of Human Genetics 94, 599–610, April 3, 2014 605
which, as we have shown, existing prioritization tools are
underpowered. These analyses thus demonstrate Phevor’s
utility by using real clinical examples.
A Gene-Disease Association for NFKB2
We identified a family affected by autosomal-dominant,
early-onset hypogammaglobulinemia with variable auto-
immune features and adrenal insufficiency. Blood samples
were obtained from the affected mother, the unaffected
father, and their two affected children (family A). Blood
was also obtained from a fourth, unrelated affected indi-
vidual with the same phenotype (family B). Sequencing
was performed as described in Chen et al.,4 and variant
annotation was performed with the VAAST Annotation
Tool (VAT).3
Exome data from the four individuals in family A and
the affected individual in family B were then analyzed
with VAAST.2,3 In family A, this analysis identified a
deletion (c.2564delA [RefSeq accession number
NM_002502.4], resulting in p.Lys855Serfs*7) in NFKB2
(MIM 164012). VAAST identified a second NFKB2 allele
(c.2557C>T [p.Arg853*]) in family B. Subsequent immu-
noblot analysis and immunofluorescence microscopy of
transformed B cells from affected individuals showed
that theNFKB2mutations affect phosphorylation and pro-
teasomal processing of the p100 NFKB2 to its p52 deriva-
tive and, ultimately, p52 nuclear translocation.4
Figure 5A shows the results of running ANNOVAR (top
left panel) and VAAST (top right panel) on the union of
all variants identified in the affected children and mother
from family A and the affected individual from family B.
The x axes of the Manhattan plots in Figure 5A are the
genomic coordinates of the candidate genes. The y axes
show the log10 value of the ANNOVAR score, VAAST p
value, or Phevor score depending upon the method.
For purposes of comparison to VAAST, we transformed
the ANNOVAR scores to frequencies by dividing the num-
ber of candidates by the total number of annotated human
genes—hence the ‘‘shelf’’ of candidates in the ANNOVAR
plot at y ¼ 1.14 (about 13.8% of human genes). Both
ANNOVAR and VAAST identified a number of equally
likely candidate genes. NFKB2 (shown in red) was among
them in both analyses.
The lower panel of Figure 5A presents the results of
postprocessing these same ANNOVAR and VAAST output
fileswith theuse of Phevor, aswell as a Phenomizer-derived,
HPO-based phenotype description consisting of terms
‘‘recurrent infections’’ (HPO:0002719) and ‘‘abnormality
of humoral immunity’’ (HPO:0005368). Phevor identified
a single best candidate,NFKB2, by using the VAASToutput,
and the same gene ranked second with the ANNOVAR
output. Functional follow-up studies established NFKB2—
hence the noncanonical NF-kB signaling pathway—as a
genetic etiology for this primary immunodeficiency syn-
drome.4 Thus, these analyses demonstrate Phevor’s ability
to identify a human gene not currently associated with a
disease or phenotype in the HPO, DO, or MPO.606 The American Journal of Human Genetics 94, 599–610, April 3, 2An Atypical Phenotype Caused by a Dominant Allele
of STAT1
The proband is a 12-year-old male with severe diarrhea in
the context of intestinal inflammation, total villous atro-
phy, and hypothyroidism. He required total parenteral
nutrition to support growth, resulting inmultiple hospital-
izations for central-line-associated bloodstream infections.
During multidisciplinary comprehensive clinical evalua-
tion, we considered a diagnosis of X-linked immunodysre-
gulation, polyendocrinopathy, and enteropathy (IPEX
syndrome [MIM 304790]), but clinical sequencing of
FOXP3 (MIM 300292) and IL2RA (MIM 147730), genes
associated with IPEX,29,30 revealed no pathologic variants.
His clinical picture was life threatening, warranting
hematopoietic stem cell transplantation despite diagnostic
uncertainty. Prior to pretransplant myeloablation, DNA
was obtained from the proband and both parents.
Figure 5B shows the results of ANNOVAR and VAAST
analysis using the proband’s exome. As was the case for
NFKB2, both ANNOVAR and VAAST were underpowered
to distinguish the disease-associated gene and causative
alleles from a background of other likely candidates. Phe-
vor analyses of these same data, together with a phenotype
description consisting of the HPO terms ‘‘hyopthryoidism’’
(HP:0000812), ‘‘paronychia’’ (HP:0001818), ‘‘autoimmu-
nity’’ (HP:0002960), and ‘‘abnormality of the intestine’’
(HP:0002242), identified a single gene, STAT1 (MIM
600555), as the third-ranked candidate in the ANNOVAR
outputs and the best candidate in the VAAST analyses
(lower panels of Figure 5B). Subsequent analyses of the
proband’s parents determined that the top-scoring variant
in the VAAST-Phevor run was a single STAT1 de novo
mutation (c.1154C>T [RefSeq NM_139266.2]) affecting
the DNA-binding region of STAT1 (p.Thr385Met [RefSeq
NP_009330.1]). We confirmed the variant by Sanger
sequencing.
Multiple-protein-sequence alignment shows conserva-
tion across phyla at this amino acid position (data not
shown). Moreover, gain-of-function mutations in STAT1
cause immune-mediated human disease,31 and STAT1
encodes a transcription factor that regulates FOXP3.32
Functional studies have indicated that this mutation leads
to an overexpression of STAT1,32–34 suggesting gain-of-
function mutation as a mechanism. Supporting this
conclusion are recent studies reporting that this same allele
causes chronic mucocutaneous candidiasis35 and an IPEX-
like syndrome.32 These results highlight Phevor’s ability to
use only a single affected exome to identify a mutation
located in a known disease-associated gene and producing
an atypical phenotype.
A Mutation in a Known Disease-Associated Gene,
ABCB11
The proband is a 6-month-old infant with an undiagnosed
liver disease phenotypically similar to progressive familial
intrahepatic cholestasis.36 To identify mutations in the
proband, we performed exome sequencing on the affected014
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Figure 5. Phevor Analyses of Three
Clinical Cases
Plotted on the x axes of each Manhattan
plot are the genomic coordinates of the
candidate genes. The y axes show the
log10 value of the ANNOVAR score, VAAST
p value, or Phevor score depending upon
the panel. Black, filled circles denote top
ranked gene(s), all of which had either
the same ANNOVAR score or the same
VAAST p value. Red circles denote the
gene containing disease-causing allele(s).
For purposes of comparison to VAAST,
we transformed the ANNOVAR scores to
frequencies by dividing the number of
gene candidates identified by ANNOVAR
by the total number of annotated human
genes.
(A) Phevor identified NFKB2 as a disease-
associated gene. (Top) Results of running
ANNOVAR (left) and VAAST (right) on
the union of variants identified in affected
members of family A and those in the
affected individual from family B. Both
ANNOVAR and VAAST identified a large
number of equally likely candidate genes.
NFKB2 (shown in red) was among them
in both cases. (Bottom) Phevor identified
a single best candidate, NFKB2, by using
the VAAST output, and NFKB2 was ranked
second with the ANNOVAR output (two
other genes were tied for first place).
(B) Phevor identified a de novo variant
in STAT1 as responsible for a previously
undescribed phenotype in an already
disease-associated gene. (Top) Results of
running ANNOVAR (left) and VAAST
(right) on the single affected individual’s
exome. Both ANNOVAR and VAAST iden-
tified multiple candidate genes. STAT1
(shown in red) was among them in both
cases. (Bottom) Phevor identified a single
best candidate, STAT1, by using the VAAST
output. STAT1was the third best candidate
with the ANNOVAR output.
(C) Phevor identified a mutation in
ABCB11, a known disease-associated
gene. (Top) Results of running ANNOVAR
(left) and VAAST (right) on the single
affected child’s exome. Both ANNOVAR
and VAAST identified a number of equally
likely candidate genes. ABCB11 (shown in
red) was among them. (Bottom) Phevor
identified a single best candidate,
ABCB11, by using the ANNOVAR and
VAAST outputs.individual and both parents. Sequencing and bioinformat-
ics processing were performed as described in the Material
and Methods.
For these Phevor analyses, a single HPO phenotype
term was used: ‘‘intrahepatic cholestasis’’ (HP:0001406).
As shown in Figure 5C, Phevor analysis identified a single
candidate gene (ABCB11) in the proband’s exome
sequence.
Mutations in ABCB11 (MIM 603201) are known to
cause progressive familial intrahepatic cholestasis type 2.
The variants identified by VAAST, and supported as causa-The Amtive by Phevor, form a compound heterozygote in the
proband. We confirmed these variants by Sanger
sequencing (see Material and Method). The paternal
variant (c.3332T>C [RefSeq NM_003742.2], leading to
p.Phe1111Ser) and the maternal variant (c.890A>G
[p.Glu297Gly]) are both considered highly damaging
by SIFT. The maternal variant is known to cause intrahe-
patic cholestasis,37 whereas the paternal mutation is not
currently associated with disease. These results demon-
strate Phevor’s ability to use only a single affected exome
to identify a previously unreported mutation located in aerican Journal of Human Genetics 94, 599–610, April 3, 2014 607
known disease-associated gene and present in trans to a
known disease-causing allele.Discussion
We have presented a series of benchmark and clinical
applications demonstrating that Phevor provides an effec-
tive means of improving the diagnostic power of widely
used variant-prioritization tools. These results demonstrate
that Phevor is especially useful for single-exome and small,
family-based analyses, the most commonly occurring clin-
ical scenarios and ones for which existing variant-prioriti-
zation tools are most inaccurate and underpowered.
As we have shown, Phevor’s ability to improve the accu-
racy of variant-prioritization tools is the result of its ability
to relate phenotype anddisease concepts inontologies such
as the HPO and DO to gene function, process, and location
concepts modeled by the GO. This allows Phevor to model
key genetic-disease features that are not taken into account
by existing methods that employ phenotype information
for variant prioritization.10,20 For example, paralogous
genes often produce similar diseases38 because they have
similar functions, operate in similar biological processes,
and are located in the same cellular compartments.
Phevor scores take into account not only the evidence
that a gene is associated with an individual’s illness but
also the evidence that it is not. In typical whole-exome
searches, every variant-prioritization tool identifies many
genes harboring what it considers to be deleterious muta-
tions. Often themost damaging of them are found in genes
without any known phenotype associating them with the
disease of interest; moreover, in practice, highly delete-
rious alleles are often false-positive variant calls. Phevor
successfully downweights these genes and alleles, causing
the target gene to climb in rank as an indirect result. This
phenomenon is well illustrated by the fact that Phevor
improved the accuracy of variant-prioritization and
genome-wide search tools even when provided with an
incorrect phenotype description, e.g., Figure 4. This result
underscores the consistency of Phevor’s approach; it also
has some important implications, namely that the lack of
previous disease association, weak phylogenetic conserva-
tion, and the lack of GO annotations for a gene are (weak)
prima facie evidence against disease association.
The interplay of all of the above factors is well illustrated
by the clinical applications we present from the Utah
Genome Project. For these analyses, we employed Phevor
in tandem with ANNOVAR and VAAST to identify
disease-causing alleles. All three cases involved small case
cohorts containing either related individuals or single
affected exomes. For all of these cases, variant prioriti-
zation alone was insufficient to identify the causative
alleles, whereas when combined with Phevor, these same
data revealed a single candidate. These analyses demon-
strate Phevor’s ability to use real clinical examples to iden-
tify a previously unreported mutation present in trans to608 The American Journal of Human Genetics 94, 599–610, April 3, 2a known disease-causing allele (ABCB11), dominant
mutations in a gene not previously associated with the
disease phenotype (NFKB2), and a de novo dominant allele
located in an known disease-associated gene (STAT1) and
producing an atypical phenotype. Collectively, these cases
illustrate that Phevor can improve diagnostic accuracy for
individuals with typical or atypical disease phenotypes and
that it can also use information latent in ontologies to
discover disease-causing alleles in genes not previously
associated with human disease.
The incorporation of new ontologies and gene-pathway
information into Phevor is an active area of development.
Phevor can employ any variant-prioritization tool and any
ontology, so long as the ontology has gene annotations
and is available in OBO format.39 Over 50 biomedical
ontologies, many satisfying both criteria, are available at
the Open Biological and Biomedical Ontologies (OBO)
Foundry. Thus, Phevor’s approach should also prove useful
for nonmodel-organism and agricultural studies. Such
applications raise interesting points. For the analyses pre-
sented here, we have used the MPO to leverage model-
organism phenotype data to improve diagnostic power
for humans. For application to model organisms, novel
organisms, and agriculture, the HPO could be used in a
manner analogous to that of the MPO in the analyses pre-
sented here, i.e., Phevor could provide a systematic means
to bring human disease knowledge and human gene anno-
tations to bear for nonmodel-organism and agricultural
studies. A publicly available Phevor web server and test
data sets are available online.Supplemental Data
Supplemental Data include five figures and one table and can be
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